Information For Authors
- Manuscript Submission Guidelines
- Author Benefits Program
- Open Access Policy
- NIH/HHMI Wellcome Trust Policies
- Self-Archiving Policy
Mary Ann Liebert, Inc. Submission Benefits Package
Your submission to Metabolic Syndrome and Related Disorders provides you with robust tools and support to ensure maximum impact and readership for your work. By submitting your manuscript, you’ll receive:
- Rapid, rigorous peer-review and editorial attention
- Immediate deposit to PubMed and other indexing services upon online publication
- Exposure to thousands of thought-leaders in your field, maximizing readers, citations, and downloads
- Fast Track online-ahead-of-print publication
- Global availability in over 170 countries
- Open Access publication options
Submitting Your Manuscript
Submitting your manuscript to Metabolic Syndrome and Related Disorders delivers a comprehensive benefits program that ensures high-quality review of your research and maximum impact for your work. Metabolic Syndrome and Related Disorders carries a manuscript processing charge* of $49.00 USD upon submission of each new manuscript.
Upon payment, you will be provided a Manuscript Submission Code, and will be prompted to enter this information when uploading your files to our peer-review system. Please note: Securing a token does not automatically create an account in our peer-review system. If you do not already have an account, you will be asked to create one before you can begin your submission.
Submissions do not need to be completed at once. Submitting authors/agents may begin the submission process, save their work, and return to the site to complete the upload(s) at a later time. There is no limit on the number of times one can save their work and subsequently resume the submission. Doing so will not incur additional charges.
All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.
Click here to submit your paper via our fast and user-friendly electronic submission system.
Processing charges and submission codes are NOT required for revisions to previously submitted papers. To upload a revision of a paper, the submitting author should log in to their Author Center at http://mc.manuscriptcentral.com/metabolic and click on “Revised Manuscripts in Draft.” The paper will appear in this area, and the submitting author will be able to upload revised files without paying any charges or entering a submission code.
Please be sure to follow the Instructions for Authors below on Manuscript Preparation. Authors whose submissions do not comply with the Instructions for Authors will have their papers un-submitted so that the file(s) may be adjusted accordingly. Directions regarding the necessary corrective actions will be provided in an email to the corresponding author at the time the paper is un-submitted. The submitting author/agent will then be provided the opportunity to re-upload the corrected file(s). If a paper is un-submitted, the paper will reside in the corresponding author’s “Author Center” as a draft, and the submitting author/agent will be able to make the necessary adjustments and re-upload the paper without incurring another manuscript processing charge.
*The manuscript processing charge is independent of editorial decision and is non-refundable.
Statement of Purpose and Policy
Metabolic Syndrome and Related Disorders provides an interdisciplinary forum to explore the pathophysiology, recognition, and treatment of the cluster of conditions associated with the evolving entity of metabolic syndrome. These include but are not limited to: central obesity, endothelial dysfunction, insulin resistance, dyslipidemia, glucose intolerance, type 2 diabetes, prothrombotic and pro-inflammatory states, hypertension, cardiovascular disease, and polycystic ovarian syndrome (PCOS). The Journal welcomes clinical and translational studies, research conducted in animal models, and molecular and cellular research. Manuscripts must not contain material that has been reported elsewhere.
The Journal accepts both original contributions and Brief Reviews. Brief Reviews are usually solicited by the Editor or Associate Editors and should be on a relevant topic . Also Brief Reviews should be restricted to approximately 3500 words and 50 references.
Letters to the Editor(s) are welcomed, but with a 500 word limit and no more than (1) table OR figure, and with a maximum of four (4) references. Perspectives / Commentaries / Editorials are invited contributions on hot toipcs in obesity, metabolic syndrome, hyperlipidemia, and diabetes. These should not exceed 2,000 words and may include up to 30 references. Perspective pieces should include a short abstract of less than 150 words.
All submissions to the Journal are subject to peer review. Authors are encouraged, but not required, to supply the names and email addresses of three to four individuals who are considered qualified to review the submitted material, as well as the names of individuals whom the authors would prefer not be selected as a reviewer. However, the review selection is ultimately at the discretion of the Editor.
Preparation of Manuscript
Type manuscripts double-spaced. Leave ample margins on sides, top and bottom. Original manuscripts must be no longer than 3,000 words.
The title page should include the authors’ names, academic degrees, and affiliations, the funding source (if appropriate), and a running title of up to 45 characters. Please indicate the name, complete mailing address, phone number, fax number, and e-mail address of the author to whom correspondence should be addressed. The second page should consist of an abstract of no more than 250 words. Abstracts of original articles should contain four paragraphs labeled as: Background, Methods, Results, and Conclusions. Abstracts of reviews should contain a single unstructured paragraph.
IRB and Patient Release Information (reproduced, in part, from ICMJE’s website)
When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Helsinki Declaration as revised in 2013. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.
Patients have a right to privacy that should not be violated without informed consent. Identifying information, including names, initials, or hospital numbers, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that an identifiable patient be shown the manuscript to be published. Authors should disclose to these patients whether any potential identifiable material might be available via the Internet as well as in print after publication. Patient consent should be written and archived with the journal, the authors, or both, as dictated by local regulations or laws. Applicable laws vary from locale to locale, and journals should establish their own policies with legal guidance.
Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity.
When informed consent has been obtained, it should be indicated in the published article, either as part of the text, or as a footnote/legend to a figure, table, etc.
Acceptable forms of consent statements are emails or letters. The Journal does not provide a generic patient release form.
Animal Ethics and Welfare
When reporting experiments on animals, authors should indicate whether institutional and national standards for the care and use of laboratory animals were followed. Further guidance on animal research ethics is available from the International Association of Veterinary Editors’ Consensus Author Guidelines on Animal Ethics and Welfare
Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at http://www.icmje.org/index.htlm#conflicts for further guidance. If no conflicts exist, the authors must state “No competing financial interests exist."
Tables and Illustrations
Each table with its title must appear on a separate page. Use Arabic numerals to number tables. Each table must stand alone, (i.e., contain all necessary information in the caption), be cited in text, and the table itself must be understood independently of the text. Details of experimental conditions should be included in the table footnotes. Information that appears in the text should not be repeated in the table, and tables should not contain data that can be given in the text in one or two sentences. Tables should be submitted as Microsoft word files, on separate pages from the text of the manuscript. All art should be submitted as TIFF or EPS files. Color, halftones, and grayscale should be at a minimum 300 dpi resolution. Line art should be at a minimum 900 dpi resolution. Color must be saved as CYMK. RGB color files will not work. PowerPoint or Excel files cannot be uploaded. A list of figure legends should be supplied on a separate page at the end of the manuscript, double spaced. We encourage the submission of color figures. Please contact the publisher for color-printing costs.
When naming your figure files, please label them with the first author's last name, followed by a period (.), and then list the figure number. Ex: Smith.0123. Fig1. Label figures and tables inside the files in addition to naming the file with the figure or table number. (ie: When figures or table files are opened, the figure or table number should appear inside the file.)
Please upload individual files of all manuscript material — do NOT upload a single PDF file containing all text, figure, and table files of your paper. Once all individual files are uploaded on to Manuscript Central, the system will automatically create a single PDF proof for you and the peer-review process.
Abbreviations of journal titles should follow MEDLINE.
List references in consecutive numerical order (not alphabetically). All subsequent reference citations should be to the original number. Cite all references in the text or tables using superscript citations. Unpublished data and personal communications should not be listed as references.
References to journal articles should include (1) authors (list first three, then et al.), (2) title, (3) journal name (as abbreviated in MEDLINE), (4) year, (5) volume number, and (6) inclusive page numbers, in that order.
References to books should include: (1) authors, (2) chapter title (if any), (3) editor or author, (4) title of book, (5) city of publication, (6) publisher, and (7) year, in that order. Volume and edition numbers, specific pages, and name of translator should be included when appropriate. The author is responsible for the accuracy and completeness of the references and for their correct text citation.
7. Aljada A, Garg R, Ghanim, H, et al. Nuclear factor-KappaB suppressive and inhibitor-KappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an anti-inflammatory action. J Clin Endocrinol Metab, 2001, 11:224-238.
8. Vinson, G.P, Anderson, D.C, Evidence of Hypertension, Adrenal Glands, Vascular System, and Hypertension, Bristol, UK: Society for Endocrinology; 1997: 1-52.
The author must obtain permission to reproduce figures, tables, and text from previously published material. Written permission must be obtained from the original copyright holder (generally the publisher, not the author or editor) of the journal or book concerned. An appropriate credit line should be included in the figure legend or table footnote, and full publication information should be included in the reference list. Written permission must be obtained from the author of any unpublished material and should accompany the manuscript.
Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.
The Journal is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215. Telephone: (914) 740–2100; fax: (914) 740–2101.
Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) option
Does your research funder have an open access mandate or would you like to expand the dissemination of your research?
The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.
The benefits of Liebert Open Access include:
- High visibility; open access articles are freely available online upon publication
- You retain copyright with the open access license allowing broad dissemination of your research
- You can freely share your article in repositories and research networks without restrictions
- Easy compliance with open access mandates
- Rigorous editorial and peer-review
- Targeted email announcement featuring a direct link to article
Identification and Marketing
Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.
Copyright and Licensing
If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Ordering Open Access
Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email firstname.lastname@example.org.
Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form. You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.
Publishing biomedical or biotechnology research?
Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.
*Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.
Browse journals in the Liebert Open Access portfolio:
NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.
Publishing in Subscription Journals
By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.
Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12 month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.
The final published article (version of record) can never be archived in a repository, preprint server, or research network.
Publishing Open Access
Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Access option allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email email@example.com or visit Liebert Open Access for more information.